This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.
After a leak of Alberta’s provincial voters list, experts say the cost is dire and the government response inadequate. ‘Our data is in the wind, and that is a terrifying prospect.’
